About this trial
The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are:
* Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment?
Participants will:
* Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).
Eligibility criteria
Qualifiers
Receiving chemotherapy at the UPMC Hillman Cancer Center for any solid tumor cancer at any stage with at least two cycles remaining;
age 18 years or older;
ability to read and write in English;
sufficient performance status to participate in research (e.g., Karnofsky performance status of 60-100%); and
Disqualifiers
under 18 years old; and
unable to read and write in English
Trial design
Treatments tested in this trial
- Mobile Symptom Monitoring and Alert App
Treatment groups
Sponsors and collaborators
University of Pittsburgh
Lead sponsor
National Cancer Institute (NCI)
Collaborator